Literature DB >> 31588824

How to Pick Out the "Unreal" Gleason 3 + 3 Patients: A Nomogram for More Precise Active Surveillance Protocol in Low-Risk Prostate Cancer in a Chinese Population.

Feng Qi1,2, Kai Zhu1, Yifei Cheng1, Lixin Hua1, Gong Cheng1.   

Abstract

OBJECTIVE: To develop a nomogram for selecting the "unreal" Gleason score (GS) 3 + 3 patients in biopsy GS 3 + 3 prostate cancer (PCa) patients.
METHODS: Patients who were newly diagnosed with PCa by biopsy and underwent radical prostatectomy in the First Affiliated Hospital of Nanjing Medical University from January 2009 to October 2018 were enrolled. Comparisons were made between GS 3 + 3 and higher grade PCa patients. Logistic regression analysis was performed to determine the risk factors for the "unreal" GS 3 + 3 PCa in biopsy GS 3 + 3 patients. Then, a nomogram was developed to predict the probability of "unreal" GS 3 + 3 PCa according to the results of multivariate analysis. Finally, receiver operating characteristic and decision curve analysis (DCA) curves were structured to identify the efficiency of the predictive model.
RESULTS: Compared to higher GS grade, biopsy GS 3 + 3 had greater upgrade risk (P < 0.05) while a lower proportion of positive surgical margins, seminal vesicle invasion, extra-prostatic extension, lymph node invasion, and nerve invasion (all P < 0.05). Multivariate analysis showed that age, PSAD, prostate imaging reporting and data system (PI-RADS) score and biopsy positive cores were significant risk factors for "unreal" GS 3 + 3. A nomogram was developed utilizing these factors with high prediction performance (area under curve = 0.924). Furthermore, DCA curve suggested that this predictive model was effective.
CONCLUSIONS: The nomogram identified the probability of "unreal" GS 3 + 3 PCa in biopsy GS 3 + 3 PCa patients, which was of great value for clinical guidance in low risk PCa therapy.

Entities:  

Keywords:  Gleason score; active surveillance; low risk; nomogram; prostate cancer; surgery

Mesh:

Year:  2019        PMID: 31588824     DOI: 10.1080/08941939.2019.1669745

Source DB:  PubMed          Journal:  J Invest Surg        ISSN: 0894-1939            Impact factor:   2.533


  3 in total

1.  Predicting Prostate Cancer Upgrading of Biopsy Gleason Grade Group at Radical Prostatectomy Using Machine Learning-Assisted Decision-Support Models.

Authors:  Hailang Liu; Kun Tang; Ejun Peng; Liang Wang; Ding Xia; Zhiqiang Chen
Journal:  Cancer Manag Res       Date:  2020-12-22       Impact factor: 3.989

2.  The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.

Authors:  Arnas Bakavičius; Mingailė Drevinskaitė; Kristina Daniūnaitė; Marija Barisienė; Sonata Jarmalaitė; Feliksas Jankevičius
Journal:  Medicina (Kaunas)       Date:  2020-02-04       Impact factor: 2.430

3.  CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score ≥ 8 in Prostate Cancer.

Authors:  Xiao-Ping Qin; Qi-Ji Lu; Cheng-Huizi Yang; Jue Wang; Jian-Fan Chen; Kan Liu; Xin Chen; Jing Zhou; Yu-Hang Pan; Yong-Hong Li; Shan-Cheng Ren; Jiu-Min Liu; Wei-Peng Liu; Hui-Jun Qian; Xian-Lin Yi; Cai-Yong Lai; Li-Jun Qu; Xin Gao; Yu-Sheng Xu; Zheng Chen; Yu-Min Zhuo
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.